Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.

[1]  A. Gennery,et al.  Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT) , 2017, Bone Marrow Transplantation.

[2]  H. Einsele,et al.  Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party , 2016, Leukemia.

[3]  F. Prósper,et al.  Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. , 2016, Blood.

[4]  B. Barlogie,et al.  American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[6]  G. Tricot,et al.  Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  N. Burwick,et al.  A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma , 2014, Bone Marrow Transplantation.

[8]  M. Beksac,et al.  Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. , 2013, Blood.

[9]  J. Bourhis,et al.  Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy , 2013, Haematologica.

[10]  R. Fanin,et al.  Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  N. Kröger,et al.  Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  H. Einsele,et al.  Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  N. Geller,et al.  Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. , 2011, The Lancet. Oncology.

[14]  H. Einsele,et al.  International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Lokhorst,et al.  Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells , 2009, Leukemia.

[16]  J. S. San Miguel,et al.  A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. , 2008, Blood.

[17]  D. Blaise,et al.  High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma , 2008, Haematologica.

[18]  R. Fanin,et al.  A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.

[19]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[20]  Jason McCoy,et al.  Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  N. Russell,et al.  Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning – evidence for a superior outcome using melphalan combined with total body irradiation , 2005, British journal of haematology.

[23]  T. Therneau,et al.  Clinical course of patients with relapsed multiple myeloma. , 2004, Mayo Clinic proceedings.

[24]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[25]  P. Sonneveld,et al.  Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[27]  R. Storb,et al.  Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. , 1996, Blood.

[28]  A. Hagenbeek,et al.  Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[30]  A. Krishnan,et al.  Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  I. Yakoub-Agha,et al.  Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple , 2005 .

[32]  B. Barlogie,et al.  Treatment of multiple myeloma. , 2004, Blood.